Like please_老虎社区_美港股上老虎

Sunshine88
2021-08-24

Like please

Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday

The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi

Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":835722325,"tweetId":"835722325","gmtCreate":1629757253367,"gmtModify":1631889907884,"author":{"id":3586140387931872,"idStr":"3586140387931872","authorId":3586140387931872,"authorIdStr":"3586140387931872","name":"Sunshine88","avatar":"https://static.tigerbbs.com/d4c6c15baca9f47c383ec0a6ca31c710","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like please</p></body></html>","htmlText":"<html><head></head><body><p>Like please</p></body></html>","text":"Like please","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/835722325","repostId":1130387472,"repostType":4,"repost":{"id":"1130387472","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629732233,"share":"https://ttm.financial/m/news/1130387472?lang=&edition=full","pubTime":"2021-08-23 23:23","market":"us","language":"en","title":"Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1130387472","media":"Benzinga","summary":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemi","content":"<p>The&nbsp;FDA has approved&nbsp;<b><a href=\"https://laohu8.com/S/XERS\">Xeris Pharmaceuticals Inc</a> Inc's</b>&nbsp;(NASDAQ:&nbsp;XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.</p>\n<p>Gvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.</p>\n<p>It eliminates the need for reconstitution.</p>\n<p>With the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.</p>\n<p>The approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).</p>\n<p>Xeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.</p>\n<p><b>Price Action:</b>&nbsp;XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-23 23:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>The&nbsp;FDA has approved&nbsp;<b><a href=\"https://laohu8.com/S/XERS\">Xeris Pharmaceuticals Inc</a> Inc's</b>&nbsp;(NASDAQ:&nbsp;XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.</p>\n<p>Gvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.</p>\n<p>It eliminates the need for reconstitution.</p>\n<p>With the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.</p>\n<p>The approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).</p>\n<p>Xeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.</p>\n<p><b>Price Action:</b>&nbsp;XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XERS":"Xeris制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130387472","content_text":"The FDA has approved Xeris Pharmaceuticals Inc Inc's (NASDAQ: XERS) Gvoke Kit for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nGvoke Kit is the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\nIt eliminates the need for reconstitution.\nWith the approval, Xeris will begin manufacturing scale-up immediately and anticipates Gvoke Kit availability in early Q1 of 2022.\nThe approval was supported by a pharmacokinetic study demonstrating bioequivalence of a 1 mg Gvoke dose administered via a vial and syringe kit (Gvoke Kit) to that of 1 mg Gvoke administered as a pre-filled syringe (Gvoke PFS).\nXeris has already received FDA approval in 2019 for Gvoke PFS and Gvoke HypoPen (glucagon injection) for severe hypoglycemia in pediatric and adult patients with diabetes ages two years and above.\nPrice Action: XERS shares are up 27.3% at $2.80 during the market session on the last check Monday.","news_type":1,"symbols_score_info":{"XERS":0.9}},"isVote":1,"tweetType":1,"viewCount":1244,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

Why Is Xeris Pharmaceuticals (XERS) Stock Shining On Monday

评论（1）

热议股票